John R. Stuelpnagel - 11 Aug 2026 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Reporting relationship: Director
Issuer ticker: TXG
Reported as of: 11 Aug 2026
Net transaction value: -$1,155,055
SEC form: 4
Accepted by SEC: 13 Aug 2026, 16:11:23 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Randy Wu, as Attorney-in-Fact for John R. Stuelpnagel

Key filing fact

John R. Stuelpnagel filed Form 4 for 10x Genomics, Inc. (TXG) on 13 Aug 2026.

Key facts

This page summarizes John R. Stuelpnagel's Form 4 filing for 10x Genomics, Inc. (TXG).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 16:11.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: -$1,155,055.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001189140 Primary reporting owner

STUELPNAGEL JOHN R

Relationship: Director
Address: C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON
Signature: /s/ Randy Wu, as Attorney-in-Fact for John R. Stuelpnagel
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXG transaction

Class A Common Stock

Sale

Transaction value: $978,880
Shares: -17,000
Change %: -4.6%
Price: $57.58
Shares after: 351,436
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

TXG transaction

Class A Common Stock

Sale

Transaction value: $176,175
Shares: -3,000
Change %: -0.85%
Price: $58.72
Shares after: 348,436
Date: 11 Aug 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.